Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Oktober 2018 09:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Grows Scientific Leadership with Two New Appointments

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene...
10. September 2018 13:58 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference

CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit...
27. August 2018 16:01 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Announces Transition of Chief Medical Officer

CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D.,...
16. August 2018 16:01 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process

CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA...
06. August 2018 16:05 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2018 Results and Update

Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...
06. August 2018 16:01 ET | Quelle: Editas Medicine, Inc.

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care EDIT-101 is Editas Medicine’s experimental CRISPR genome editing...
30. Juli 2018 16:02 ET | Quelle: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results

CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
13. Juni 2018 09:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine to Participate in The JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor...
18. Mai 2018 17:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates

CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that...
08. Mai 2018 08:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of...

Vorherige Seite